STOCK TITAN

Turn Therapeutics (TTRX) Financials

TTRX NASDAQ
Trailing 12 months to September 30, 2026
Revenue Not reported for the trailing 12 months
Net Income -$12.8M YoY not available
EPS (Diluted) -$0.43 n/m YoY
Operating Cash Flow -$5.3M n/m YoY
Market Cap $261.4M as of Nov 16, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 45.9x on $5.7M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TTRX SEC filings page.

This page shows Turn Therapeutics Inc. (TTRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TTRX FY2025

Turn Therapeutics expanded its balance sheet mainly through financing, while operating spending still produced losses and cash outflows.

The 2025 balance-sheet repair came from financing rather than operations: financing cash flow was $6.9M versus operating cash flow of -$2.6M. Equity turned positive, but reported returns remained negative, indicating that the stronger balance sheet does not yet reflect profitable operations.

The expense mix changed sharply: SG&A rose 260.6% while R&D rose only 8.0%. That pattern indicates the larger spending increase was administrative rather than development-focused, so the loss expansion was not driven primarily by research investment.

Short-term liquidity tightened from a 1.6x current ratio in FY2024 to 0.9x in FY2025, even as current assets reached $5.2M. Current liabilities were $6.0M, leaving near-term obligations larger than reported current resources; the supplied liquidity measure equaled 18.9 months of the latest annual operating outflow.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Turn Therapeutics Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
2/6

Turn Therapeutics Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Turn Therapeutics Inc. reported a net loss of $3.2M while operations used $2.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income
-$6.2M
YoYn/m
QoQn/m

Turn Therapeutics Inc. reported a net loss of $6.2M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.21
YoYn/m
QoQn/m

Turn Therapeutics Inc. earned -$0.21 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt
$9.4M
YoY+1736.3%
QoQ-5.2%

Turn Therapeutics Inc. held $9.4M in cash against $5.7M in long-term debt as of Q3 2026.

Shares Outstanding
31M
YoY+3.8%
QoQ+2.6%

Turn Therapeutics Inc. had 31M shares outstanding in Q3 2026. This represents an increase of 3.8% from the same quarter a year earlier. Against the prior quarter it is up 2.6%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-109.5%
YoY+268.3pp
QoQ+742.2pp

Turn Therapeutics Inc.'s quarterly ROE was -109.5% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 268.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 742.2 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$605K
YoY+281.3%
QoQ+27.4%

Turn Therapeutics Inc. invested $605K in research and development in Q3 2026. This represents an increase of 281.3% from the same quarter a year earlier. Against the prior quarter it is up 27.4%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

TTRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TTRX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$605K+281.3%$475K+657.9%$109K+1081.9%$35K$159K+3.5%$63K$9KN/A
SG&A Expenses$1.4M-21.4%$1.2M-11.6%$1.1M+202.5%$2.2M$1.8M+237.7%$1.3M$376KN/A
Operating Income-$2.0Mn/m-$1.6Mn/m-$1.2Mn/m-$2.2M-$1.9Mn/m-$1.4M-$385KN/A
Interest Expense$0$241KN/AN/AN/AN/AN/AN/A
Net Income-$6.2Mn/m-$5.8Mn/m-$971Kn/m$279K-$1.9Mn/m-$1.2M-$329KN/A
EPS (Basic)-$0.21n/m-$0.20n/m-$0.03n/m$0.01n/m-$0.07n/m-$0.05-$0.01-$0.02
EPS (Diluted)-$0.21n/m-$0.20n/m-$0.03n/m$0.01n/m-$0.07n/m-$0.05-$0.01-$0.02
Diluted Shares (Avg)30M+7.7%30M+8.3%29M+9.3%N/A28M+5.0%27M27MN/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.

TTRX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TTRX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$16.3M+280.4%$17.0M$18.6M$12.2M+493.6%$4.3MN/AN/A$2.0M
Current Assets$11.1M+236.3%$10.4M$11.5M$5.2M+373.3%$3.3MN/AN/A$1.1M
Cash & Equivalents$9.4M+1736.3%$9.9M+211.9%$11.0M+600.1%$4.0M+708.3%$514K+3.1%$3.2M$1.6M$498K
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0$0$0
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0$0$0
Total Liabilities$10.7M+180.9%$16.3M$12.5M$7.5M+235.8%$3.8MN/AN/A$2.2M
Current Liabilities$3.5M+50.6%$8.8M$5.1M$6.0M+748.0%$2.3MN/AN/A$708K
Non-Current Liabilities$7.2M+383.6%$7.5M$7.4M$1.5M-3.0%$1.5MN/AN/A$1.5M
Long-Term Debt$5.7M$6.1M$5.9MN/AN/AN/AN/AN/A
Total Equity$5.7M+1029.4%$687K-61.3%$6.1M+647.2%$4.7Mn/m$504Kn/m$1.8M$819K-$177K
Retained Earnings-$35.4Mn/m-$29.2M-$23.4M-$22.4Mn/m-$22.7MN/AN/A-$19.2M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

TTRX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TTRX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$1.5Mn/m-$923Kn/m-$1.6Mn/m-$1.2Mn/m-$589K-$500K-$298K-$431K
Stock-Based CompensationN/AN/A$281K+266.6%N/AN/AN/A$77KN/A
Investing Cash Flow-$16Kn/m-$6K-$12K-$31Kn/m-$90KN/AN/A-$8K
Financing Cash Flow$1.6M+176.0%$1-100.0%$7.8M+680.1%$3.2M+508.5%$595K$2.1M$998K$522K

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

TTRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TTRX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-109.5%+268.3pp-851.7%-781.8pp-15.9%+24.3pp5.9%-377.8%-69.9%-40.1%N/A
Return on Assets-38.1%+6.2pp-34.5%-5.2%2.3%-44.3%N/AN/AN/A
Current Ratio3.19+1.8x1.192.230.87-0.7x1.43N/AN/A1.55
Debt-to-Equity1.018.830.97N/AN/AN/AN/AN/A
Liabilities-to-Equity1.87-5.7x23.692.051.607.53N/AN/AN/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Note: The current ratio is below 1.0 (0.87), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Turn Therapeutics Inc. TTRX FY2025 N/A -$3.2M N/A $261.4M —
Century Therapeutics, Inc. IPSC FY2025 $109.2M -$9.6M -8.8% $297.8M 60/100
Allogene Therapeutics, Inc. ALLO FY2025 $0 -$190.9M N/A $279.6M —
Ocugen, Inc. OCGN FY2025 $4.4M -$67.8M N/A $262.3M 43/100
Nautilus Biotechnolgy, Inc. NAUT FY2025 N/A -$59.0M N/A $267.5M —
Inovio Pharmaceuticals, Inc. INO FY2025 $65K -$84.9M N/A $262.2M —

Frequently Asked Questions

No, Turn Therapeutics Inc. (TTRX) reported a net loss of $12.8M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $3.2M.

Turn Therapeutics Inc. (TTRX) reported diluted earnings per share of -$0.12 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Turn Therapeutics Inc. (TTRX) had EBITDA of -$5.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Turn Therapeutics Inc. (TTRX) has a return on equity of -68.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Turn Therapeutics Inc. (TTRX) recorded an outflow of $2.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Turn Therapeutics Inc. (TTRX) had $12.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Turn Therapeutics Inc. (TTRX) invested $266K in research and development during fiscal year 2025.

Turn Therapeutics Inc. (TTRX) had 30M shares outstanding as of fiscal year 2025.

Turn Therapeutics Inc. (TTRX) had a current ratio of 0.87 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Turn Therapeutics Inc. (TTRX) had a liabilities-to-equity ratio of 1.60 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Turn Therapeutics Inc. (TTRX) had a return on assets of -26.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Turn Therapeutics Inc. (TTRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $261.4M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Turn Therapeutics Inc. (TTRX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $261.4M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Turn Therapeutics Inc. (TTRX) held $4.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.6M over that year. Dividing the one by the other, the reported balance equals about 19 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Turn Therapeutics Inc. (TTRX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Turn Therapeutics Inc. (TTRX) reported a net loss of $3.2M while operations used $2.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top